- Home
- HTLM vs IMMX Comparison
HTLM vs IMMX Comparison
Compare HTLM & IMMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HTLM
- IMMX
- Stock Information
- Founded
- HTLM 2014
- IMMX 2014
- Country
- HTLM Singapore
- IMMX United States
- Employees
- HTLM N/A
- IMMX N/A
- Industry
- HTLM
- IMMX Medicinal Chemicals and Botanical Products
- Sector
- HTLM
- IMMX Health Care
- Exchange
- HTLM NYSE
- IMMX Nasdaq
- Market Cap
- HTLM 58.8M
- IMMX 50.1M
- IPO Year
- HTLM 2024
- IMMX 2021
- Fundamental
- Price
- HTLM $3.75
- IMMX $1.71
- Analyst Decision
- HTLM
- IMMX Strong Buy
- Analyst Count
- HTLM 0
- IMMX 1
- Target Price
- HTLM N/A
- IMMX $7.00
- AVG Volume (30 Days)
- HTLM 12.8K
- IMMX 41.7K
- Earning Date
- HTLM 04-07-2025
- IMMX 05-08-2025
- Dividend Yield
- HTLM N/A
- IMMX N/A
- EPS Growth
- HTLM N/A
- IMMX N/A
- EPS
- HTLM N/A
- IMMX N/A
- Revenue
- HTLM $3,057,723.00
- IMMX N/A
- Revenue This Year
- HTLM N/A
- IMMX N/A
- Revenue Next Year
- HTLM N/A
- IMMX N/A
- P/E Ratio
- HTLM N/A
- IMMX N/A
- Revenue Growth
- HTLM N/A
- IMMX N/A
- 52 Week Low
- HTLM $2.57
- IMMX $1.26
- 52 Week High
- HTLM $13.74
- IMMX $2.71
- Technical
- Relative Strength Index (RSI)
- HTLM N/A
- IMMX 53.28
- Support Level
- HTLM N/A
- IMMX $1.61
- Resistance Level
- HTLM N/A
- IMMX $1.57
- Average True Range (ATR)
- HTLM 0.00
- IMMX 0.15
- MACD
- HTLM 0.00
- IMMX 0.02
- Stochastic Oscillator
- HTLM 0.00
- IMMX 82.37
About HTLM HOMESTOLIFE LTD
Homestolife Ltd is a home furniture retailers that offers and sells customized furniture solutions in Singapore. It has six retail store locations that sell furniture manufactured from China and other Asian countries.
About IMMX Immix Biopharma Inc.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.